financetom
Business
financetom
/
Business
/
Fifth Third Bancorp's quarterly profit rises on fee income boost
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Fifth Third Bancorp's quarterly profit rises on fee income boost
Jan 21, 2025 5:49 AM

(Reuters) - Fifth Third Bancorp ( FITB ) reported a rise in fourth-quarter profit on Tuesday, driven by a recovery in dealmaking across the industry and higher wealth and asset management fees.

Shares of the lender were up 1.5% in premarket trading. They had jumped 22.6% in 2024.

Banks have benefited from a resurgence in dealmaking activity, fueled by improving economic confidence and greater political certainty. Expectations of additional rate cuts and business-friendly policies under President Donald Trump have fueled optimism for a further revival in investment banking.

Fifth Third Bancorp's ( FITB ) capital markets fees jumped 16% from the year earlier to $123 million, while its wealth and asset management revenue rose 11% to $163 million.

The lender's assets under management jumped about 17% to $69 billion.

These gains mirror trends seen by larger rivals, benefiting from a rebound of investment banking activity.

Fifth Third's net interest income (NII), the difference between what banks pay customers on deposits and earn as interest on loans, rose 1.5% to $1.44 billion.

While Fifth Third forecast that NII will remain stable in the first quarter versus the fourth quarter, the bank expects it to grow between 5% and 6% in 2025.

However, provision for credit losses of the Cincinnati, Ohio-based bank jumped to $179 million in the quarter from $55 million a year earlier.

Banks have been allocating larger reserves to cover for potential losses due to bad loans, as elevated interest rates heightened worries about borrowers defaulting on their mortgages.

Net income available to common shareholders rose to $582 million, or 85 cents per share, in the three months ended Dec. 31, from $492 million, or 72 cents per share, a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kraken Robotics Swings to Q1 Net Income, Posts Record Revenue
Kraken Robotics Swings to Q1 Net Income, Posts Record Revenue
May 29, 2024
08:07 AM EDT, 05/29/2024 (MT Newswires) -- Kraken Robotics ( KRKNF ) said on Wednesday that it swung to a net profit in the first quarter on the back of record revenue. Kraken posted a net income of $2.2 million, improving from a loss of $1.3 million, after revenue surged 175% to a record $20.9 million from $7.6 million. Adjusted...
Abercrombie & Fitch Fiscal Q1 Adjusted Earnings, Sales Climb; Raises Fiscal 2024 Sales Outlook
Abercrombie & Fitch Fiscal Q1 Adjusted Earnings, Sales Climb; Raises Fiscal 2024 Sales Outlook
May 29, 2024
08:04 AM EDT, 05/29/2024 (MT Newswires) -- Abercrombie & Fitch ( ANF ) reported fiscal Q1 adjusted earnings Wednesday of $2.14 per diluted share, up from $0.39 a year earlier. Analysts polled by Capital IQ expected $1.72. Net sales for the quarter ended May 4 were $1.02 billion, up from $836 million a year earlier. Analysts surveyed by Capital IQ...
Market Chatter: Banco Bilbao Vizcaya Argentaria Boosting Houston Office for Sustainability Business
Market Chatter: Banco Bilbao Vizcaya Argentaria Boosting Houston Office for Sustainability Business
May 29, 2024
08:06 AM EDT, 05/29/2024 (MT Newswires) -- Banco Bilbao Vizcaya Argentaria ( BBVA ) is boosting its Houston office as it intends to make the city a sustainability business hub, Bloomberg reported Wednesday, citing unnamed sources familiar with the plan. The company has already relocated some employees from its Madrid headquarters, the report added, citing the people. The Spanish lender...
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe
Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe
May 29, 2024
08:00 AM EDT, 05/29/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Wednesday that it received orphan medicinal product designation from the European Commission for RP-A601, its gene therapy for plakophilin-2-related arrhythmogenic cardiomyopathy, or PKP2-ACM. The designation is based on the European Medicines Agency's positive opinion, the company said. Orphan designation provides financial and regulatory benefits, including protocol assistance...
Copyright 2023-2026 - www.financetom.com All Rights Reserved